Comparative Pharmacology
Head-to-head clinical analysis: AVELOX versus LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVELOX versus LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
AVELOX vs LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
Levofloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
400 mg orally or intravenously once daily for 7 to 14 days depending on infection severity.
750 mg intravenously every 24 hours for 5 days. Alternatively, 500 mg intravenously every 24 hours for 7-14 days depending on infection.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in healthy adults, allowing once-daily dosing. May be prolonged in patients with renal impairment.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged in renal impairment (up to 30-50 hours in severe impairment).
Renal (approximately 45-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30% as unchanged drug and metabolites). Total recovery in urine and feces accounts for >96% of the dose.
Primarily renal excretion as unchanged drug (approximately 87% within 48 hours); less than 4% as metabolites; biliary/fecal excretion accounts for <5%.
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)